透析を必要とする腎不全の患者におけるステロイドミネラルコルチコイド受容体抗体の安全性と有効性: ランダム化制御試験の体系的レビューとメタ解析
Lonnie Pyne1, Patrick Rossignol2, Cameron Giles3
1Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
Lancet (London, England)
|August 21, 2025
まとめ
ステロイドミネラルコルチコイド受容体の抗体は,透析患者の心血管死亡率に最小限の影響を及ぼします. 特定のサブグループと非ステロイド剤についてはさらなる研究が必要である.
科学分野:
- 腎臓科
- 心臓病科
- 薬理学について
背景:
- ミネラルコルチコイド受容体対抗薬 (MRA) は,心不全および慢性腎疾患における心血管疾患の予防のために確立されています.
- 透析を必要とする末期腎疾患の患者における有効性と安全性は不明である.
研究 の 目的:
- 心血管疾患による死亡率および維持透析を受けている患者の他のアウトカムに対するMRAの効果を体系的にレビューし,メタ分析する.
主な方法:
- 2025年3月18日までのランダム化対照試験 (RCT) の体系的なレビューとメタ解析を更新しました.
- MRAとプラセボまたは標準治療を比較した維持透析を受けている成人を含む.
- 主要アウトカム: 心血管疾患による死亡; 二次的なアウトカム: 入院,高血量,副作用.
主要な成果:
- 4675人の参加者を含む19件のRCTを分析した.
- 偏差リスクの低い試験では,MRAは心血管疾患による死亡率の有意な低下を示さなかった (OR 0. 98; 95% CI 0. 80 - 1. 20).
- 絶対リスクの減少は最小限であった (1000患者年あたり1症例).
結論:
- 透析を必要とする患者の心血管死亡率には,ステロイド製のMRAはほとんど効果がないようである.
- サブグループと非ステロイドのMRAについては,十分なデータが存在しない.
- 将来の試験は,特定の患者集団とアルドステロン主導の病理生理学に焦点を当てなければならない.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:25Antihypertensive Drugs: Direct Renin Inhibitors
819
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
819
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
761
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
761
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
915
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
915